Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/28/2012

5,283$  181,906$  156,313Computation of Non-GAAP Adjusted Diluted Net Income per ShareNon-GAAP adjusted net income

$  50,611$  45,283$  181,906$  156,313Add interest expense on senior convertible notes, net of income tax

6256252,5012,501Non-GAAP adjusted diluted net income

$  51,236$  45,908$  184,407$  158,814Shares used in computing GAAP diluted net income per share

84,49390,93488,07690,081Shares used in computing Non-GAAP adjusted diluted net income per share

84,49390,93488,07690,081GAAP diluted net income  per share

$
.65$
.43$
.68$
.47Non-GAAP adjusted diluted net income  per share

$
.61$
.50$
2.09$
.76Use of Non-GAAP Financial Measures Our "non-GAAP adjusted net income" excludes the following items from GAAP net income:

1.  Non-cash interest expense: Non-GAAP adjusted net income excludes certain non-cash interest expense resulting from the change in the method of accounting for our convertible notes which became effective in 2009.  We believe that excluding the non-cash portion of our interest expense allows management and investors an alternative view of our financial results "as if" our net income reflected only the cash portion of our interest expense.  

2.  Purchase accounting and product acquisition related adjustments:  Non-GAAP adjusted net income excludes certain items related to our acquisitions. The excluded items include charges related to amortization of intangible assets arising from acquisitions, changes in the fair value of future contingent consideration and upfront fees or milestone payments under license agreements.

3.  Stock option expense: Non-GAAP adjusted net income excludes the impact of our stock compen
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... temper tantrums lately? Or an adolescent episode of hormone-clouded ... a bit of flagging memory? , ,Given that organizations ... another, it's easy to begin thinking about organizations as ... they age. It's even understandable to want a model ...
... ,Jia Hu of China - Source: Getty Images The ... every four years. They're held every year. Though this is ... year as the pervasive growth of the industry becomes part ... run every four years and last two weeks, the biotech ...
... MADISON, Wis. - Ownership and accountability is the way ... 448-bed community hospital in Madison that provides medical care ... living facility, laboratories and a home health care service. ... Methodist Hospital in 1987, Meriter includes more than 430 ...
Cached Biology Technology:Aging IT 2Aging IT 3The Olympics: A Biotech Perspective 2The Olympics: A Biotech Perspective 3Meriter IT team builds project performance through internal relationships 2Meriter IT team builds project performance through internal relationships 3Meriter IT team builds project performance through internal relationships 4
(Date:7/9/2014)... are less fit in terms of cardiorespiratory capacity, ... Moreover, southern adolescents are more obese and present ... those from the centre-north of Europe. , These ... ambitious study conducted by scientists from the University ... with 25 other European research groups. The study ...
(Date:7/9/2014)... if they are used in the right ways. ... Women,s Hospital and coauthors analyzed six use cases ... triage; decompensation (when a patient,s condition worsens); adverse ... multiple organ systems. They suspect that cost-savings benefits ... with all six scenarios will be significant. The ...
(Date:7/8/2014)... run" or as a well-deserved break, and you,ll eat less afterward. ... you,ll later eat more dessert and snacks to reward yourself. , ... involved two studies where adults were led on a 2 km ... going to be an exercise walk or a scenic walk. ... were then given lunch. Those who believed they had been ...
Breaking Biology News(10 mins):Adolescents from southern Europe are less fit and more obese than central-northern European peers 2The impact of big data on health care: Health Affairs' July issue 2
... today for the HudsonAlpha- Science 2014 Conference on ... HudsonAlpha biotechnology campus in Huntsville, Ala. The ... of this emerging scientific field. ImmunoGenomics sits at ... the use of DNA sequencing to improve disease diagnosis ...
... an oil spill, and images of fouled beaches and ... visible effects as well. For instance, even low levels ... fish embryos and larvae, reducing the likelihood that those ... for some time, but the underlying mechanism has remained ...
... by memory deficits. Basel scientists have now identified a ... is important for human brain activity, memory and the development ... online edition of the US journal Neuron . ... a telephone number - is a fundamental function of the ...
Cached Biology News:Registration opens for HudsonAlpha-Science's 2014 Conference on ImmunoGenomics 2Registration opens for HudsonAlpha-Science's 2014 Conference on ImmunoGenomics 3Scientists discover the mechanism of heart failure in fish exposed to oil spills 2Scientists discover the mechanism of heart failure in fish exposed to oil spills 3How memory and schizophrenia are connected 2
... Cycler unit is an inexpensive personal or mini ... PCR process. Lightweight, with a small footprint, it ... including the researcher's desk. , The Gene Cycler ... do not have access to a large laboratory ...
... Select Immunophosphatase Secondary Detection System is intended ... Prediluted Primary Antibody reagents, which contain rat ... of antigens by light microscopy in paraffin-embedded ... System may also be used with other ...
... RNA stain is used to stain and ... agarose gels and does not interfere with ... nm transilluminator, the stain emits a red-orange ... film or with a CCD camera-based gel ...
... efficient interfacing with mass spectrometry. Improved ... demands for benefits like these have ... routine applications. Standard HPLC systems, however, ... to operate with smaller bore columns ...
Biology Products: